Platzbecker U - Search Results

1

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M. Heinicke T, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2020 Apr;55(4):729-739. doi: 10.1038/s41409-019-0720-0. Epub 2019 Oct 23. Bone Marrow Transplant. 2020. PMID: 31645668

2

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.

Bornhäuser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, Plettig R, Röllig C, Naumann R, Kroschinsky F, Neubauer A, Ehninger G. Bornhäuser M, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2000 Jul;26(2):119-25. doi: 10.1038/sj.bmt.1702500. Bone Marrow Transplant. 2000. PMID: 10918420

3

Acute heart failure after allogeneic blood stem cell transplantation due to massive myocardial infiltration by cytotoxic T cells of donor origin.

Platzbecker U, Klingel K, Thiede C, Freiberg-Richter J, Schuh D, Ehninger G, Kandolf R, Bornhäuser M. Platzbecker U, et al. Bone Marrow Transplant. 2001 Jan;27(1):107-9. doi: 10.1038/sj.bmt.1702744. Bone Marrow Transplant. 2001. PMID: 11244447

4

Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

Platzbecker U, Thiede C, Freiberg-Richter J, Röllig C, Helwig A, Schäkel U, Mohr B, Schaich M, Ehninger G, Bornhäuser M. Platzbecker U, et al. Bone Marrow Transplant. 2001 Mar;27(5):543-6. doi: 10.1038/sj.bmt.1702819. Bone Marrow Transplant. 2001. PMID: 11313690

5

Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation.

Platzbecker U, Bandt D, Thiede C, Helwig A, Freiberg-Richter J, Schuler U, Plettig R, Geissler G, Rethwilm A, Ehninger G, Bornhäuser M. Platzbecker U, et al. Transplantation. 2001 Apr 15;71(7):880-5. doi: 10.1097/00007890-200104150-00010. Transplantation. 2001. PMID: 11349720

6

Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation.

Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A, Thiede HM, Schäfer-Eckart K, Ehninger G, Bornhäuser M. Jenke A, et al. Among authors: platzbecker u. Clin Transplant. 2001 Jun;15(3):176-84. doi: 10.1034/j.1399-0012.2001.150306.x. Clin Transplant. 2001. PMID: 11389708 Clinical Trial.

7

Double lumen port access in patients receiving allogeneic blood stem cell transplantation.

Platzbecker U, Illmer T, Schaich M, Freiberg-Richter J, Helwig A, Plettig R, Jenke A, Ehninger G, Bornhäuser M. Platzbecker U, et al. Bone Marrow Transplant. 2001 Dec;28(11):1067-72. doi: 10.1038/sj.bmt.1703285. Bone Marrow Transplant. 2001. PMID: 11781618 Clinical Trial.

8

Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.

Strodtbeck D, Bornhäuser M, Hänel M, Lerche L, Schaich M, Illmer T, Thiede C, Geissler G, Herbst R, Ehninger G, Platzbecker U. Strodtbeck D, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2005 Dec;36(12):1083-8. doi: 10.1038/sj.bmt.1705176. Bone Marrow Transplant. 2005. PMID: 16247435

9

Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

Haentzschel I, Freiberg-Richter J, Platzbecker U, Kiani A, Schetelig J, Illmer T, Ehninger G, Schleyer E, Bornhäuser M. Haentzschel I, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2008 Jul;42(2):113-20. doi: 10.1038/bmt.2008.85. Epub 2008 Mar 24. Bone Marrow Transplant. 2008. PMID: 18362900

10

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.

von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, Bornhäuser M. von Bonin M, et al. Among authors: platzbecker u. Bone Marrow Transplant. 2009 Feb;43(3):245-51. doi: 10.1038/bmt.2008.316. Epub 2008 Sep 29. Bone Marrow Transplant. 2009. PMID: 18820709

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

569 results

Search Page